Pembrolizumab: Promising Response Rate in Pretreated Metastatic Gastric Cancer
Pembrolizumab has shown a promising response rate in patients with pretreated metastatic gastric cancer, according to late-breaking results from the KEYNOTE-059 trial presented today at the ESMO 2017 Congress in Madrid.